

Dermatological Conditions

Reference Number: F4601
Date of Response: 10th May 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Request and Royal Devon's Eastern FOI Office Response

Q1. How many patients were treated in last 4 months by the Dermatology department with each of the following:

- Abrocitinib: **0 patients**
- Acitretin: **94 patients**
- Alitretinoin: **15 patients**
- Azathioprine: **0 patients**
- Baricitinib: ***<5**
- Ciclosporin: **18 patients**
- Dupilumab: **107 patients**
- Methotrexate: **147 patients**
- Mycophenolate mofetil: **7 patients**
- Pimecrolimus: ***<5**
- Tacrolimus ointment: **29 patients**
- Tralokinumab: **0 patients**
- Upadacitinib: ***<5**

Q2. Of the patients treated in the last 4 months with any of the products listed in Q1, how many patients were paediatric (age 17 or under)?

20 Patients that were treated in the last four months using the products listed in question 1 were aged 17 or under.

Q3. How many patients were treated in the last 4 months with phototherapy (UVB or PUVA) for atopic Dermatitis ONLY? ***<5**

***<5 We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated with Baricitinib, Pimecrolimus, Upadacitinib and Phototherapy is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and all principles of the Data Protection Act 1998.**

Section 40(2) of the FOIA states that information is exempt from disclosure if it constitutes the personal data of a third party and its disclosure under the FOIA would breach any of the data protection principles or section 10 of the Data Protection Act 1998

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.